Molecular target for Alzheimers treatment unveiledNovember 6th, 2008 - 1:20 pm ICT by ANI
London, Nov 6 (ANI): A team of researchers has shown that a molecule called Cyclophilin D (CypD) interacts with amyloid beta (Aa) peptide, the main constituent of plaques in the brains of Alzheimer’’s patients, within the mitochondria.
The study involving a transgenic mouse model of Alzheimers disease suggests that blocking CypD and development of surrounding mitochondrial targets may be viable therapeutic strategies for the prevention and treatment of Alzheimers disease, reports Nature.
Study leader Shi Du Yan, professor of clinical pathology in the Department’’s of Pathology and Surgery and in the Taub Institute for Research on Alzheimer’’s Disease and the Aging Brain at Columbia University Medical Center, says that this work describes how this mitochondrial process may be linked to synaptic failure in Alzheimers disease.
During the study, Dr. Yan and colleagues observed that the cortical mitochondria isolated from Alzheimers disease mice lacking CypD were resistant to Aa- and Ca2+-induced mitochondria swelling and permeability transition, increased calcium buffering capacity, and attenuate generation of mitochondrial ROS.
Also, they found that CypD-deficient neurons protect against Aa- and oxidative stress-induced cell death.
Importantly, they researchers found that deficiency of CycD greatly improved the learning, memory, and synaptic function of an Alzheimers disease mouse model and alleviated Aa-mediated reduction of long-term potentiation (LTP).
Thus, the CypD/Aa-mediated mitochondrial permeability transition pore directly links to the cellular and synaptic perturbation relevant to the pathogenesis of Alzheimer’’s disease.
The study is published in the Sept. 21 on-line edition of Nature Medicine. (ANI)
- Indications of Alzheimer's may be evident decades before first signs - Mar 29, 2011
- Protein that shuttles RNA into mitochrondria discovered - Aug 08, 2010
- Potential therapeutic target for improving long-term memory identified - Jan 27, 2011
- Potential therapeutic target for Parkinson's, Alzheimer's identified - Mar 12, 2011
- How Alzheimer's plaques lead to loss of nitric oxide in brain - Jan 11, 2011
- New finding shows promise in the fight against Alzheimer's - Jan 27, 2011
- Chronic high cholesterol diet leads to brain damage: Study - Nov 25, 2010
- Cancer-causing H. pylori bug spurs cell death - Nov 02, 2011
- Tobacco-derived compound prevents memory loss in Alzheimer's - Apr 28, 2011
- Factor X in coffee boosts protection against Alzheimer's - Jun 30, 2011
- Study reveals how ageing impacts the brain - Nov 08, 2010
- Antioxidant may prevent alcohol-induced liver damage - May 03, 2011
- Sleep disorders are early signs of Alzheimer's - Sep 06, 2012
- Why Alzheimer's drug is both safe and effective - Aug 19, 2010
- How neuroglobin protects against Alzheimer's - Aug 03, 2010
Tags: aging brain, alzheimers disease, ca2, cell death, clinical pathology, columbia university medical, long term potentiation, mitochondria, molecular target, nature medicine, nature study, pathogenesis, peptide, perturbation, pore, study leader, taub institute, therapeutic strategies, transgenic mouse model, university medical center